Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Bleomycin sulfate
Drug ID BADD_D00281
Description A complex of related glycopeptide antibiotics from Streptomyces verticillus consisting of bleomycin A2 and B2 (B2 CAS # 9060-10-0). It inhibits DNA metabolism and is used as an antineoplastic, especially for solid tumors. Bleomycin A2 is used as the representative structure for Bleomycin.
Indications and Usage For palliative treatment in the management malignant neoplasm (trachea, bronchus, lung), squamous cell carcinoma, and lymphomas.
Marketing Status approved; investigational
ATC Code L01DC01
DrugBank ID DB00290
KEGG ID D02177
MeSH ID D001761
PubChem ID 72466
TTD Drug ID D06UVD
NDC Product Code 71288-107; 58623-0033; 63323-136; 63323-137; 53183-7003; 71288-106
UNII 7DP3NTV15T
Synonyms Bleomycin | Bleomycins | BLEO-cell | BLEO cell | BLEOcell | Bleolem | Bléomycine Bellon | Bellon, Bléomycine | Bleomycin A2 | Bleomycin A(2) | Bleomycin B2 | Bleomycin B(2) | Bleomycin Sulfate | Sulfate, Bleomycin | Bleomycinum Mack | Mack, Bleomycinum | Blenoxane | Blanoxan | Bleomicina
Chemical Information
Molecular Formula C55H85N17O25S4
CAS Registry Number 9041-93-4
SMILES CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O) OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6 =NC(=CS6)C(=O)NCCC[S+](C)C)O.OS(=O)(=O)[O-]
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Alopecia23.02.02.001--
Blister23.03.01.001; 12.01.06.002--Not Available
Blood glucose decreased13.02.02.001--Not Available
Cerebral arteritis17.08.02.004; 24.12.02.002--Not Available
Cerebrovascular accident24.03.05.001; 17.08.01.007--
Chills15.05.03.016; 08.01.09.001--
Confusional state19.13.01.001; 17.02.03.005--
Dyspnoea02.11.05.003; 22.02.01.004--
Erythema23.03.06.001--Not Available
Haemolytic uraemic syndrome20.01.03.011; 01.06.02.001--
Hyperkeratosis23.01.01.001--
Hypotension24.06.03.002--
Interstitial lung disease22.01.02.003; 10.02.01.033--Not Available
Local reaction08.01.03.012--Not Available
Malaise08.01.01.003--
Myocardial infarction24.04.04.009; 02.02.02.007--
Nail disorder23.02.05.002--
Oedema14.05.06.010; 08.01.07.006--Not Available
Pain of skin23.03.03.003--
Paradoxical pressor response24.08.02.003--Not Available
Phlebitis24.12.03.004; 12.02.01.002--
Pneumonitis22.01.01.006--
Pruritus23.03.12.001--
Pulmonary fibrosis22.01.02.006--
Pyrexia08.05.02.003--
Rales22.12.01.011--Not Available
Rash23.03.13.001--Not Available
Raynaud's phenomenon24.04.03.003--Not Available
Scleroderma23.03.02.005; 15.06.01.002; 10.04.07.001--Not Available
Skin hyperpigmentation23.05.01.003--
The 1th Page    1 2    Next   Last    Total 2 Pages